Bionovate Technologies Corp. (BIIO)

Overview

Bionovate Technologies Corp., originally established as MJP International Ltd., transitioned to its current identity in December 2017, reflecting a focused reorientation towards innovative healthcare solutions. The company, rooted in Cham, Switzerland since 2010, has carved a niche in the medical device landscape, emphasizing the development of automated treatments for age spots. As a testament to its strategic expansion and commitment to integrating advanced technology in healthcare, Bionovate Technologies became a valued subsidiary of Human Data AG by October 7, 2020. Targeting a global market, the company envisions its state-of-the-art systems being integral to the offerings of physicians and spas worldwide, thereby enhancing the quality and accessibility of age spot treatments.

Products and Services

Bionovate Technologies Corp. is singularly focused on innovating in the domain of age spot treatment, leveraging automation and computing technology to offer next-generation solutions to its clientele. The products and services under development are aimed at revolutionizing how age spots are treated, with the following offerings:

• Automated Treatment System for Age Spots: This flagship solution epitomizes Bionovate Technologies' commitment to advancing medical aesthetics. Harnessing the power of automation and sophisticated computing, the proposed system promises a transformative approach to treating age spots. Designed for versatility, it aspires to address pigmentation issues across diverse body parts, ensuring a comprehensive treatment protocol. The intent behind this innovation is not only to elevate treatment efficacy but also to redefine user convenience and safety, laying the groundwork for a new standard in cosmetic care.
• Global Distribution Network: Understanding the necessity of accessibility to revolutionize age spot treatment, Bionovate Technologies aims to construct a robust distribution network that encompasses physicians and spas around the globe. This strategic move is expected to democratize access to advanced treatment solutions, ensuring that the benefits of their pioneering system can be leveraged by a broad spectrum of users. By fostering strategic partnerships and focusing on outreach, the company seeks to make its automated treatment system a ubiquitous tool in the aesthetic and medical fields.